Currently, the treatment that targets only tumor cells has reached a bottleneck. With the rapid development of cell biology, molecular biology, proteomics, and genomics theory and technology, the important role of TME (including stroma, blood vessels, immune cells and factors, metabolites, etc.) in the occurrence, development, metastasis, treatment resistance of malignant tumors and the treatment-related adverse reactions has been widely recognized. Molecular genetics, genomics, and bioinformatics are increasingly being applied to understanding TME, helping us better understand the interaction between TME and tumor cells. In this way, it can provide a valuable research basis for restraining tumor-promoting behavior and enhancing tumor-suppressive behavior of TME and provide new targets and tools for the treatment of malignant tumors.
The purpose of this special issue is to explore the beneficial (tumor-suppressive) or harmful (tumor-promoting) shaping of TME (including stroma, blood vessels, immune cells, cytokines, growth factors, metabolites, etc.) by various factors, including genes, genomes, gene products, and genetic phenotypes, and find out the underlying relationships and patterns. We hope to gain a more comprehensive understanding of how TME is created, how TME interacts with tumor cells, and how TME can be targeted to achieve the best tumor suppression effect and clinical treatment outcome. This research topic will collect a set of articles, including original research, bioinformatics analysis, and literature review, aiming to provide a series of new ideas and perspectives and to build a basis for finding novel ways to modify TME and improve the therapeutic efficacy of malignant tumors.
Original studies, brief reports, reviews, and methodological papers are welcome. The focus of this study is to explore the potential mechanisms of certain genes, gene products, and genetic phenotypes shaping and regulating the TME. These may include, but are not limited to:
• Identification of novel genes involved in the regulation and shaping of TME.
• Identify potential targets for intervention in the TME to achieve beneficial antitumor outcomes.
• To identify genes and models related to TME that have predictive value for clinical efficacy and adverse reactions.
• In vivo or in vitro models or clinical studies related to the modification of the TME.
• Genetic studies related to the TME
Please note that the in silico studies based on solely one database, e.g. TCGA or GEO, will not be considered for review.
Currently, the treatment that targets only tumor cells has reached a bottleneck. With the rapid development of cell biology, molecular biology, proteomics, and genomics theory and technology, the important role of TME (including stroma, blood vessels, immune cells and factors, metabolites, etc.) in the occurrence, development, metastasis, treatment resistance of malignant tumors and the treatment-related adverse reactions has been widely recognized. Molecular genetics, genomics, and bioinformatics are increasingly being applied to understanding TME, helping us better understand the interaction between TME and tumor cells. In this way, it can provide a valuable research basis for restraining tumor-promoting behavior and enhancing tumor-suppressive behavior of TME and provide new targets and tools for the treatment of malignant tumors.
The purpose of this special issue is to explore the beneficial (tumor-suppressive) or harmful (tumor-promoting) shaping of TME (including stroma, blood vessels, immune cells, cytokines, growth factors, metabolites, etc.) by various factors, including genes, genomes, gene products, and genetic phenotypes, and find out the underlying relationships and patterns. We hope to gain a more comprehensive understanding of how TME is created, how TME interacts with tumor cells, and how TME can be targeted to achieve the best tumor suppression effect and clinical treatment outcome. This research topic will collect a set of articles, including original research, bioinformatics analysis, and literature review, aiming to provide a series of new ideas and perspectives and to build a basis for finding novel ways to modify TME and improve the therapeutic efficacy of malignant tumors.
Original studies, brief reports, reviews, and methodological papers are welcome. The focus of this study is to explore the potential mechanisms of certain genes, gene products, and genetic phenotypes shaping and regulating the TME. These may include, but are not limited to:
• Identification of novel genes involved in the regulation and shaping of TME.
• Identify potential targets for intervention in the TME to achieve beneficial antitumor outcomes.
• To identify genes and models related to TME that have predictive value for clinical efficacy and adverse reactions.
• In vivo or in vitro models or clinical studies related to the modification of the TME.
• Genetic studies related to the TME
Please note that the in silico studies based on solely one database, e.g. TCGA or GEO, will not be considered for review.
